ABL209 Bispecific ADC Strategy Highlighted Ahead of Phase 1 Initiation

According to a recent LinkedIn post from BioSpectator Inc, Korean biotech company ABL Bio is moving toward first dosing in a Phase 1 trial of its EGFRxMUC1 bispecific ADC ABL209 (also known as NEOK002) in the second quarter, and has begun outlining its development strategy. The post reports that at AACR 2026, a senior researcher described ABL209 as a 1+1 bispecific antibody targeting EGFR and MUC1, conjugated with the TOP1 inhibitor payload tevatecan.

The LinkedIn post notes that the same payload is used in CLDN18.2 ADC IBI343, which is reported to show antitumor activity in clinical studies, with dose escalation up to 6 mpk and no observed interstitial lung disease. The post also highlights a differentiated antibody design, indicating that ABL209’s affinity for EGFR has been reduced roughly 60-fold versus marketed EGFR antibodies to potentially mitigate toxicity concerns.

In addition, the post suggests that ABL209 targets a different MUC1 domain than previous MUC1-directed agents, which have reportedly suffered efficacy losses because portions of MUC1 are shed in tumor tissue. Based on this design, the researcher is said to have presented three key data sets supporting ABL209’s competitiveness, and the preclinical results have been published in the journal Molecular Cancer Therapeutics.

For investors following the ADC space, the content points to ABL209 as an emerging asset positioned to address historical safety and efficacy challenges around EGFR and MUC1 targeting, which could be relevant for future partnering or licensing interest. While the post focuses on scientific differentiation rather than commercial timelines, successful early clinical data could strengthen ABL Bio’s standing in oncology ADC development and may influence valuation expectations in the medium term.